The invention relates to a pharmaceutical agent for the complexation of iron. The pharmaceutical agent includes an initiator group, a polymer and a terminal group R7, and has the structure: initiator group-polymer-R7. The pharmaceutical agent further includes one or more functional hydroxamic acid groups of the type —；(C═；O)NHOH or —；(C═；O)NCH3OH.
